AumniVIDA

What does high homocysteine mean?

Updated October 31, 2026 · 32 sources · Written by the AumniVIDA team

Units

Short answer

High homocysteine, above about 15 µmol/L, usually means a folate or B12 shortfall, reduced kidney function, hypothyroidism, a drug effect or the MTHFR TT genotype with low folate. Values above 30 point to significant deficiency or kidney disease, and above 100 to inherited disorders. It predicts vascular and brain risk but rarely causes symptoms itself.

Homocysteine categories in µmol/L

15 to 30: moderate10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 to 15: within lab range, above expert target: 10 to 15 µmol/L10 to 15: within lab range, above expert target: 10 to 15 µmol/L10 to 15: within lab range, above expert target: 10 to 15 µmol/L10 to 15: within lab range, above expert target: 10 to 15 µmol/L10 to 15: within lab range, above expert target: 10 to 15 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 to 15: within lab range, above expert target: 10 to 15 µmol/L10 to 15: within lab range, above expert target: 10 to 15 µmol/L10 to 15: within lab range, above expert target: 10 to 15 µmol/L10 to 15: within lab range, above expert target: 10 to 15 µmol/L10 to 15: within lab range, above expert target: 10 to 15 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L010Probably safe at or below: 10 µmol/L11Dementia risk threshold in consensus: 11 µmol/L13VITACOG benefit above: 13 µmol/L14.5Labcorp upper limit, age 18 to 60: 14.5 µmol/L15ARUP upper limit: 15 µmol/L30Intermediate starts: 30 µmol/L40 µmol/L
10 or below: probably safe (Smith and Refsum)
0 to 10
10 to 15: within lab range, above expert target
10 to 15
15 to 30: moderate
15 to 30
30 to 100: intermediate (over 100 severe)
30 to 40
  • 10 µmol/L: Probably safe at or below
  • 11 µmol/L: Dementia risk threshold in consensus
  • 13 µmol/L: VITACOG benefit above
  • 14.5 µmol/L: Labcorp upper limit, age 18 to 60
  • 15 µmol/L: ARUP upper limit
  • 30 µmol/L: Intermediate starts
Most adults sit between 5 and 15 µmol/L. Moderate, intermediate and severe hyperhomocysteinemia start at about 15, 30 and 100 µmol/L, and the cutoffs that experts and labs use for action differ by several units.

Key takeaways

  1. 1

    Above 15 µmol/L is hyperhomocysteinemia; moderate to 30, intermediate to 100, severe beyond [1][2].

  2. 2

    In 165 patients with cardiovascular events and raised homocysteine, mostly above 30 µmol/L, 55% had B12 or folate deficiency, 15% severe kidney failure and 11% inherited disorders [1].

  3. 3

    High homocysteine itself causes no specific symptoms; symptoms come from the cause, such as B12 deficiency [3].

  4. 4

    It predicts heart disease and stroke [4], but lowering it has not reduced heart attacks [5].

What does a high homocysteine level mean?

It means homocysteine is being made faster than folate, B12 and B6 clear it, or that the kidneys clear it slowly. How high it is gives a clue to the cause.

Most adults sit between 5 and 15 µmol/L [2]. Above that, the size of the rise is the first clue:

  • 15 to 30 µmol/L, moderate. Common. Usually mild folate or B12 shortfall, lower kidney function, older age, smoking, heavy coffee, hypothyroidism or the MTHFR TT genotype with low folate [6][7].
  • 30 to 100 µmol/L, intermediate. Usually significant B12 or folate deficiency or kidney failure [1].
  • Over 100 µmol/L, severe. Points to inherited disorders such as cystathionine beta-synthase deficiency, or severe B12 deficiency [2][1].

Before drawing conclusions, check the sample conditions. A non-fasting draw after a large protein meal can read about 13% higher [8], and blood left unspun at room temperature rises about 0.7 µmol/L per hour [9]. Lab ranges also climb with age; Labcorp's upper limit is 14.5 µmol/L at 18 to 60 years and 21.3 µmol/L over 80 [10].

Homocysteine categories in µmol/L

15 to 30: moderate10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 to 15: within lab range, above expert target: 10 to 15 µmol/L10 to 15: within lab range, above expert target: 10 to 15 µmol/L10 to 15: within lab range, above expert target: 10 to 15 µmol/L10 to 15: within lab range, above expert target: 10 to 15 µmol/L10 to 15: within lab range, above expert target: 10 to 15 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 or below: probably safe (Smith and Refsum): 0 to 10 µmol/L10 to 15: within lab range, above expert target: 10 to 15 µmol/L10 to 15: within lab range, above expert target: 10 to 15 µmol/L10 to 15: within lab range, above expert target: 10 to 15 µmol/L10 to 15: within lab range, above expert target: 10 to 15 µmol/L10 to 15: within lab range, above expert target: 10 to 15 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L15 to 30: moderate: 15 to 30 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L30 to 100: intermediate (over 100 severe): 30 to 40 µmol/L010Probably safe at or below: 10 µmol/L11Dementia risk threshold in consensus: 11 µmol/L13VITACOG benefit above: 13 µmol/L14.5Labcorp upper limit, age 18 to 60: 14.5 µmol/L15ARUP upper limit: 15 µmol/L30Intermediate starts: 30 µmol/L40 µmol/L
10 or below: probably safe (Smith and Refsum)
0 to 10
10 to 15: within lab range, above expert target
10 to 15
15 to 30: moderate
15 to 30
30 to 100: intermediate (over 100 severe)
30 to 40
  • 10 µmol/L: Probably safe at or below
  • 11 µmol/L: Dementia risk threshold in consensus
  • 13 µmol/L: VITACOG benefit above
  • 14.5 µmol/L: Labcorp upper limit, age 18 to 60
  • 15 µmol/L: ARUP upper limit
  • 30 µmol/L: Intermediate starts
Most adults sit between 5 and 15 µmol/L. Moderate, intermediate and severe hyperhomocysteinemia start at about 15, 30 and 100 µmol/L, and the cutoffs that experts and labs use for action differ by several units.

What causes high homocysteine?

Low B12 or folate, reduced kidney function, hypothyroidism, metformin, the MTHFR TT genotype with low folate, smoking, heavy coffee and age. Rare inherited disorders cause the highest values.

The table lists the main causes with the size of effect reported in studies.

A few causes deserve detail:

  • B12. Long-term metformin lowered B12 by 19%, and patients who became deficient averaged 23.7 µmol/L [11]. Vegans and vegetarians without supplements run higher homocysteine than omnivores [12].
  • Folate. Folic acid fortification cut the share of US adults above 13 µmol/L from 18.7% to 9.8% [13]. Where food is fortified, folate deficiency is a less common cause.
  • Kidneys. Higher creatinine tracks higher homocysteine [6]. Kidney function is worth checking alongside the result.
  • Thyroid. Overt hypothyroidism raises homocysteine; even subclinical hypothyroidism adds about 1.16 µmol/L [14]. The TSH hub covers thyroid testing.
  • Proton pump inhibitors are often listed as a cause, but in 25,953 adults the difference was only 12.0 versus 11.6 µmol/L [15].
Causes of high homocysteine and how big their effect is.
CauseTypical effectSource
Vitamin B12 deficiency on metforminMean 23.7 µmol/L in deficient patients vs 14.9 with normal B12de Jager 2010
Low folate before fortification18.7% above 13 µmol/L, falling to 9.8% afterJacques 1999
MTHFR TT in low-folate regionsAbout 3.1 µmol/L higher than CCHolmes 2011
MTHFR TT in fortified regionsAbout 0.1 µmol/L higher than CCHolmes 2011
Heavy filtered coffee (1 L a day)1.5 µmol/L (18%) higherUrgert 2000
Heavy smoking, older age, male sexUp to 4.8 µmol/L higher than young non-smoking womenNygård 1995
Subclinical hypothyroidismAbout 1.16 µmol/L higherZhang 2020
Proton pump inhibitors12.0 vs 11.6 µmol/L, not clinically relevantLerman 2022
Severe kidney failure15% of a hospital series, mostly above 30 µmol/LLevy 2021
Inherited one-carbon disorders11% of the same series; often over 100 µmol/LLevy 2021; StatPearls

What are the symptoms of high homocysteine?

Moderately high homocysteine has no symptoms of its own. Symptoms, when present, come from the cause: B12 deficiency, kidney disease, hypothyroidism or, rarely, an inherited disorder.

Homocysteine is found on a blood test, not felt. When people with high results have symptoms, these usually reflect the underlying problem:

  • B12 deficiency can cause megaloblastic anaemia and neurological problems such as numbness, tingling, balance trouble and memory change; left untreated it can be severe [3]. Treatment should not be delayed when symptoms are strong, even if tests are borderline [16].
  • Intermediate and severe hyperhomocysteinemia has been found in patients admitted with blood clots and other cardiovascular events, and in one series it was the only vascular risk factor in about 9% [1].
  • Classical homocystinuria, the rare inherited form, damages blood vessels and bones from a young age [2][17][18].
  • Hypothyroidism brings tiredness, cold intolerance and weight gain; see the TSH hub.

Lists online that link high homocysteine to fatigue, brain fog or anxiety usually describe B12 deficiency or another cause, not homocysteine itself.

Is high homocysteine dangerous for the heart, brain and bones?

It predicts higher risk of heart disease, stroke, dementia and fractures. Trials show lowering it does not prevent heart attacks, may modestly lower stroke, and slows brain atrophy in older adults with high levels.

Heart and stroke. A 25% lower homocysteine was associated with 11% less heart disease and 19% less stroke in cohorts [4]. B-vitamin trials lowered homocysteine by about 25% without changing heart attacks (RR 1.02), with a small stroke reduction (RR 0.90) [5]. Genetic evidence points the same way: little or no coronary effect [19], some stroke effect in low-folate populations [7][20]. Risk is better judged with markers that trials have validated, such as ApoB, LDL cholesterol and lipoprotein(a).

Brain. Homocysteine above 14 µmol/L nearly doubled Alzheimer risk in Framingham [21], and consensus experts call it a modifiable risk factor [22]. B vitamins slowed brain atrophy in people with mild cognitive impairment and high homocysteine [23][24], but dementia prevention is not proven.

Bones. The top homocysteine quartile carried about 1.9 times the fracture risk in older adults [18][25]. Trials of B vitamins for fracture prevention are fewer and are not reviewed here.

Can stress raise homocysteine levels?

There is little human evidence that psychological stress itself raises homocysteine. Habits that often travel with stress, such as smoking, heavy coffee and a poor diet, do.

We found no large human study showing that psychological stress raises homocysteine. Most studies on stress and homocysteine are in animals or cells, which cannot tell you what happens in a person's blood test.

What does move homocysteine is well documented:

  • Smoking: levels climb with each cigarette per day [26].
  • Heavy coffee: a litre a day raised it by 1.5 µmol/L [27].
  • Diet low in folate: a fruit, vegetable and dairy rich diet lowered it modestly [28].
  • Inactivity: physical activity tracked with lower levels [26].

If a stressful period came with more coffee, more cigarettes and less cooking, those changes are the likelier link.

What usually happens after a high homocysteine result?

Clinicians usually repeat it under proper conditions and look for the cause: B12, MMA, folate, kidney function and thyroid. Genetic MTHFR testing is not recommended routinely.

The next steps are a clinician's call, but a typical work-up follows the causes:

  1. Repeat the test properly: fasting, seated, processed on time [29][30].
  2. Check B12 status, ideally with methylmalonic acid, which is more specific for B12 than homocysteine [16].
  3. Check folate. Serum folate is the first-line folate test [16].
  4. Check kidney and thyroid function [6][14].
  5. Review medications such as metformin [11].
  6. Consider inherited disorders if values are very high or start in childhood [1].

The American College of Medical Genetics advises against routine MTHFR testing [31], because the homocysteine level itself already shows whether the pathway is working. Treatment of an identified deficiency is straightforward; see how to lower homocysteine.

More about Homocysteine

Protocols that act on Homocysteine

Common questions

What does high homocysteine mean?

Usually a B12 or folate shortfall, reduced kidney function, hypothyroidism or the MTHFR TT genotype with low folate [6][1].

What are the symptoms of high homocysteine levels?

There are no specific symptoms. Symptoms come from the cause, such as numbness or anaemia in B12 deficiency [3].

What is the treatment for high homocysteine?

Treat the cause. Folic acid, with B12 when needed, lowers it by about a quarter [32]; the choice and dose belong with a clinician.

Is a homocysteine level of 20 high?

It falls in the moderate band of 15 to 30 µmol/L [1] and is above Labcorp's upper limit for every adult age band under 80; after 80 the limit is 21.3 µmol/L [10].

Is high homocysteine an emergency?

Usually not, but very high values above 100 µmol/L or high values with nerve symptoms need prompt medical review [2][16].

Sources

  1. 1.Levy J, Rodriguez-Guéant RM, Oussalah A, et al. Cardiovascular manifestations of intermediate and major hyperhomocysteinemia due to vitamin B12 and folate deficiency and/or inherited disorders of one-carbon metabolism: a 3.5-year retrospective cross-sectional study of consecutive patients. Am J Clin Nutr, 2021. doi:10.1093/ajcn/nqaa432
  2. 2.Son P, Lewis L. Hyperhomocysteinemia. StatPearls, 2022. PubMed 32119295
  3. 3.Hannibal L, Lysne V, Bjørke-Monsen AL, et al. Biomarkers and Algorithms for the Diagnosis of Vitamin B12 Deficiency. Front Mol Biosci, 2016. doi:10.3389/fmolb.2016.00027
  4. 4.Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA, 2002. doi:10.1001/jama.288.16.2015
  5. 5.Martí-Carvajal AJ, Solà I, Lathyris D, et al. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev, 2017. doi:10.1002/14651858.CD006612.pub5
  6. 6.Refsum H, Nurk E, Smith AD, et al. The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. J Nutr, 2006. doi:10.1093/jn/136.6.1731S
  7. 7.Holmes MV, Newcombe P, Hubacek JA, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet, 2011. doi:10.1016/S0140-6736(11)60872-6
  8. 8.Guttormsen AB, Schneede J, Fiskerstrand T, et al. Plasma concentrations of homocysteine and other aminothiol compounds are related to food intake in healthy human subjects. J Nutr, 1994. doi:10.1093/jn/124.10.1934
  9. 9.Korzun WJ, Ho QV. Stability of plasma total homocysteine concentrations in EDTA-whole blood kept on ice. Clin Lab Sci, 2000. PubMed 11586504
  10. 10.Labcorp. Homocyst(e)ine, Plasma (test 706994). Labcorp test menu, 2026. Link
  11. 11.de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ, 2010. doi:10.1136/bmj.c2181
  12. 12.Obersby D, Chappell DC, Dunnett A, et al. Plasma total homocysteine status of vegetarians compared with omnivores: a systematic review and meta-analysis. Br J Nutr, 2013. doi:10.1017/S000711451200520X
  13. 13.Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med, 1999. doi:10.1056/NEJM199905133401901
  14. 14.Zhang SF, Li LZ, Zhang W, et al. Association Between Plasma Homocysteine Levels and Subclinical Hypothyroidism in Adult Subjects: A Meta-Analysis. Horm Metab Res, 2020. doi:10.1055/a-1199-2633
  15. 15.Lerman TT, Cohen E, Sochat T, et al. Proton pump inhibitor use and its effect on vitamin B12 and homocysteine levels among men and women: A large cross-sectional study. Am J Med Sci, 2022. doi:10.1016/j.amjms.2022.07.006
  16. 16.Devalia V, Hamilton MS, Molloy AM. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. Br J Haematol, 2014. doi:10.1111/bjh.12959
  17. 17.McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol, 1969. PubMed 5792556
  18. 18.van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med, 2004. doi:10.1056/NEJMoa032546
  19. 19.Clarke R, Bennett DA, Parish S, et al. Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PLoS Med, 2012. doi:10.1371/journal.pmed.1001177
  20. 20.Bennett DA, Parish S, Millwood IY, et al. MTHFR and risk of stroke and heart disease in a low-folate population: a prospective study of 156 000 Chinese adults. Int J Epidemiol, 2023. doi:10.1093/ije/dyad147
  21. 21.Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med, 2002. doi:10.1056/NEJMoa011613
  22. 22.Smith AD, Refsum H, Bottiglieri T, et al. Homocysteine and Dementia: An International Consensus Statement. J Alzheimers Dis, 2018. doi:10.3233/JAD-171042
  23. 23.Smith AD, Smith SM, de Jager CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One, 2010. doi:10.1371/journal.pone.0012244
  24. 24.Douaud G, Refsum H, de Jager CA, et al. Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A, 2013. doi:10.1073/pnas.1301816110
  25. 25.McLean RR, Jacques PF, Selhub J, et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med, 2004. doi:10.1056/NEJMoa032739
  26. 26.Nygård O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA, 1995. doi:10.1001/jama.1995.03530190040032
  27. 27.Urgert R, van Vliet T, Zock PL, et al. Heavy coffee consumption and plasma homocysteine: a randomized controlled trial in healthy volunteers. Am J Clin Nutr, 2000. doi:10.1093/ajcn/72.5.1107
  28. 28.Appel LJ, Miller ER 3rd, Jee SH, et al. Effect of dietary patterns on serum homocysteine: results of a randomized, controlled feeding study. Circulation, 2000. doi:10.1161/01.cir.102.8.852
  29. 29.ARUP Laboratories. Homocysteine, Total (test 0099869). ARUP Laboratory Test Directory, 2026. Link
  30. 30.Rasmussen K, Moller J, Lyngbak M. Within-person variation of plasma homocysteine and effects of posture and tourniquet application. Clin Chem, 1999. doi:10.1093/clinchem/45.10.1850
  31. 31.Hickey SE, Curry CJ, Toriello HV. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genet Med, 2013. doi:10.1038/gim.2012.165
  32. 32.Homocysteine Lowering Trialists' Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr, 2005. doi:10.1093/ajcn/82.4.806

AumniVIDA explains health data for general wellness. Talk to your clinician about your own results, medication and diagnosis.

Track your Homocysteine over time.

Bring every lab report into one history, compare results with your own baseline, and ask the coach what changed. Join the iPhone beta.

Join the iPhone beta. We send TestFlight invitations in batches.